CN100372944C - Pde4d在筛选治疗动脉粥样硬化的药物中的用途 - Google Patents

Pde4d在筛选治疗动脉粥样硬化的药物中的用途 Download PDF

Info

Publication number
CN100372944C
CN100372944C CNB2004800096278A CN200480009627A CN100372944C CN 100372944 C CN100372944 C CN 100372944C CN B2004800096278 A CNB2004800096278 A CN B2004800096278A CN 200480009627 A CN200480009627 A CN 200480009627A CN 100372944 C CN100372944 C CN 100372944C
Authority
CN
China
Prior art keywords
pde4d
pde4d7
pde4
acid
pde4d5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800096278A
Other languages
English (en)
Chinese (zh)
Other versions
CN1771329A (zh
Inventor
S·埃弗斯
J·芬格勒
J·海姆伯
S·格雷塔斯多蒂尔
J·R·古尔切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Decode Genetics ehf
Original Assignee
F Hoffmann La Roche AG
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Decode Genetics ehf filed Critical F Hoffmann La Roche AG
Publication of CN1771329A publication Critical patent/CN1771329A/zh
Application granted granted Critical
Publication of CN100372944C publication Critical patent/CN100372944C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNB2004800096278A 2003-04-10 2004-04-07 Pde4d在筛选治疗动脉粥样硬化的药物中的用途 Expired - Fee Related CN100372944C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007993.3 2003-04-10
EP03007993 2003-04-10

Publications (2)

Publication Number Publication Date
CN1771329A CN1771329A (zh) 2006-05-10
CN100372944C true CN100372944C (zh) 2008-03-05

Family

ID=33155123

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800096278A Expired - Fee Related CN100372944C (zh) 2003-04-10 2004-04-07 Pde4d在筛选治疗动脉粥样硬化的药物中的用途

Country Status (6)

Country Link
EP (1) EP1616024A1 (ja)
JP (1) JP2006522594A (ja)
CN (1) CN100372944C (ja)
AU (1) AU2004227089A1 (ja)
CA (1) CA2521303A1 (ja)
WO (1) WO2004090157A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743904A3 (en) * 2005-07-13 2007-02-14 F. Hoffmann-La Roche Ag Guinea pig chymase
JP6148007B2 (ja) * 2009-05-12 2017-06-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
US11827938B2 (en) 2015-05-29 2023-11-28 Koninklijke Philips N.V. Methods of prostate cancer prognosis
JP7184771B2 (ja) 2016-12-01 2022-12-06 コーニンクレッカ フィリップス エヌ ヴェ ヒトホスホジエステラーゼ４ｄバリアント７の発現に基づくリスクスコア

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074992A2 (en) * 2001-03-19 2002-09-26 Decode Genetics Ehf. Phosphodiesterase 4d genes related to human stroke
US6500856B2 (en) * 1999-12-23 2002-12-31 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354941B2 (en) * 2000-01-31 2008-04-08 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
AU2003301894A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
EP1439221B1 (en) * 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag PDE core construct

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500856B2 (en) * 1999-12-23 2002-12-31 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2002074992A2 (en) * 2001-03-19 2002-09-26 Decode Genetics Ehf. Phosphodiesterase 4d genes related to human stroke

Also Published As

Publication number Publication date
WO2004090157A1 (en) 2004-10-21
AU2004227089A1 (en) 2004-10-21
EP1616024A1 (en) 2006-01-18
CN1771329A (zh) 2006-05-10
JP2006522594A (ja) 2006-10-05
CA2521303A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
Meléndez-López et al. Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model
Jun et al. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages.
JP2010279385A (ja) インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物
AU2021203872B2 (en) DPEP-1 binding compositions and methods of use
Guo et al. ADAMTS-1 contributes to the antifibrotic effect of captopril by accelerating the degradation of type I collagen in chronic viral myocarditis
WO2004074478A1 (ja) ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
Chen et al. The complement component 1 q (C1q) in Nile tilapia (Oreochromis niloticus): functional characterization in host defense against bacterial infection and effect on cytokine response in macrophages
Wang et al. Involvement of Fenneropenaeus chinensis cathepsin C in antiviral immunity
CN100372944C (zh) Pde4d在筛选治疗动脉粥样硬化的药物中的用途
CN103333227B (zh) 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
Kim et al. JN-2, a CXC motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model
JP2013510832A (ja) Ａ型インフルエンザウイルス感染症の治療または予防用のｐａｒ−１アンタゴニスト
EP0933423B1 (en) Meltrins
Liu et al. Molecular and functional characterization of a CD59 analogue from large yellow croaker Pseudosciana crocea
Stewart et al. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists
JP2001509014A (ja) 広範囲スペクトル発熱性外毒素アンタゴニストおよびワクチン
CA2123420A1 (en) Protease vaccine against heartworm
US8986683B2 (en) Combined use of ribonuclease and artemisinin
EP1366063B1 (en) Inhibitors of lyn-associated signal transduction (last) and the use thereof in the treatment of prostate cancer
JP6587190B2 (ja) タイトジャンクション形成制御剤及び該制御剤を含む医薬組成物
Meng et al. pik3r3b, a novel immune-related gene in Nile tilapia (Oreochromis niloticus): Identification, expression and analysis of antibacterial activity
CA2109481A1 (en) Anti-metastatic vaccine
Hasson Generation of antibodies against disintegrin and cysteine-rich domains by DNA immunization: An approach to neutralize snake venom-induced haemorrhage
Li et al. Molecular and functional characterization of a cystatin analogue in large yellow croaker (Pseudosciaena crocea)
CN101857634B (zh) 纤维蛋白溶解系统激活蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080305